An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey.
Marquis
Robert W
RW
Departments of Medicinal Chemistry, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA. Robert_W_Marquis@GSK.com
Ward
Keith W
KW
Roethke
Theresa
T
Smith
Brian R
BR
Ru
Yu
Y
Yamashita
Dennis S
DS
Tomaszek
Thaddeus A
TA
Gorycki
Peter D
PD
Cheng
H Y
HY
James
Ian E
IE
Stroup
George B
GB
Lark
Michael W
MW
Gowen
Maxine
M
Veber
Daniel F
DF
D000284:Administration, Oral; D000818:Animals; D001381:Azepines / Q000493:pharmacokinetics* / Q000494:pharmacology; D001682:Biological Availability; D056657:Cathepsin K; D002403:Cathepsins / Q000378:metabolism*; D015853:Cysteine Proteinase Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology; D006801:Humans; D051381:Rats
D001381:Azepines; D015853:Cysteine Proteinase Inhibitors; D002403:Cathepsins; C534130:CTSK protein, human; D056657:Cathepsin K; C534133:Ctsk protein, rat